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Abstract Video capsule endoscopy (VCE) has become a 
clinically accepted diagnostic modality in the last 20 years and 
has established a technological roadmap for other capsule 
endoscopy (CE) devices, incorporating microscale technology, a 
local power supply and wireless communication. However, VCE 
does not provide a therapeutic function and research in 
therapeutic capsule endoscopy (TCE) has been limited.  
This paper proposes a new route towards viable TCE based on 
multiple CE devices including essential nanoscale components. A 
first device is used for multimodal diagnosis, with quantitative 
microultrasound as a complement to video imaging. Ultrasound-
enhanced fluorescent marking of sites of pathology allows follow-
up with a second device for therapy. This is based on fluorescence 
imaging and ultrasound-mediated targeted drug delivery. 
Subsequent treatment verification and monitoring with a third 
device exploits the minimally invasive nature of CE.  
Clinical implementation of a complete patient pathway 
remains the subject of research but several key components have 
been prepared in early prototype form. These are described, 
along with gaps that remain to be filled.  
I. INTRODUCTION  
Conventional endoscopy through oral and anal routes, 
respectively, provides routine access to the upper and lower 
parts of the gastrointestinal (GI) tract. Whilst these techniques 
are minimally invasive, subjects must attend hospital, require 
sedation, and have the procedure administered by highly 
skilled clinicians. Assessment of the full length of the GI tract 
with double-balloon enteroscopy is possible, but this is a 
nonroutine procedure performed only in large healthcare 
centres.  
Video capsule endoscopy (VCE) [1] has been developed, 
introduced and accepted as a routine clinical procedure in the 
past 20 years. It is based on three areas of innovation linked to 
work in other fields: miniaturization of cameras and related 
electronic circuitry; minimal power consumption from a local 
battery; and wireless communication with a data logger. A 
fourth innovation, automated information extraction and 
interpretation is still a topic of research. Additionally, 
localization with accuracy compatible with targeted therapy 
remains impossible.  
Conventional optical endoscopy is now allied with 
multiple additional diagnostic modalities. Of these, ultrasound 
(US) has been argued to be most important [2] since it permits 
subsurface imaging of optically-opaque tissue. Its 
implementation is based on its nature as a safe, inexpensive, 
real-time technique deployed at the point of care. Resulting  
  
* This research is supported by the UK EPSRC Sonopill Programme, ref. 
GR/K034537. It previously drew support from the EU Nanoporation project, 
ref. 230674.  
S.Cochran, D.Cumming, H.Lay and H.Mulvana are with the School of 
Engineering, University of Glasgow, Glasgow, G12 8QQ, UK (Phone: +44 
141 330 3317); e-mail: sandy.cochran@glasgow.ac.uk).   
data have been shown to be amenable to quantitative analysis 
in some situations and it carries therapeutic potential through 
ultrasound-mediated targeted drug delivery (UmTDD).  
II. PROPOSED PATIENT PATHWAY  
Important components in a multimodal diagnostic CE 
device include sensing and actuation devices, a battery power 
supply, and wireless communication circuitry and an antenna. 
A therapeutic device must additionally include a reservoir and 
release mechanism for the nanotechnological therapeutic 
agent and a targeting mechanism is likely to be essential for 
non-systemic therapies. The form of a typical CE device is a 
cylinder with spherical ends, overall length 30 mm, diameter 
10 mm [3]. Hence, a solution comprising two or more separate 
devices in a theranostic combination may be needed to 
accommodate the proposed functions. This has the additional 
advantage that clinical validation may be incorporated in the 
procedure at the diagnostic stage, prior to therapy.  
The proposed patient pathway begins with a patient 
presenting with indications of  &%"*"&% )+! ) (&!%4) 
disease. The patient is subject to conventional diagnosis and a  
diagnostic CE device is administered if the diagnostic 
outcome is positive. This device generates optical and 
microultrasound (US) data identifying disease sites within the 
GI tract through quantitative analysis working at the 
nanoscale. These sites are marked with fluorescent 
nanoparticles using an US-mediated process. By reviewing 
the results manually, a clinician validates the diagnosis then 
administers a therapeutic CE device. This device can detect 
fluorescent markers but does not require diagnostic or more 
than minimal communication capabilities. Instead, available 
volume is used for a reservoir of a nanotherapeutic agent, a 
release mechanism, and US components to drive the agent 
towards the target and permeabilize the tissue to enhance 
uptake.  
Subsequently, a further CE device can be administered to 
verify disease response. The ability of CE devices to penetrate 
the full length of the gut in a minimally invasive manner thus 
allows closed loop diagnosis and therapy.   
III. RELEVANT RESULTS  
Preliminary results have been obtained for some of the 
stages in the outline procedure and the prototype CE devices 
from which these results were obtained have demonstrated 
key components though the need for a local power supply and 
wireless communication was avoided with multimodal 
tethers.  
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Nevertheless, the prototype CE devices themselves conform 
to the maximum dimensions set by current clinical practice.  
A. Microultrasound Diagnosis and Quantitative Analysis  
US uses frequencies above the conventional diagnostic 
upper limit of 20 MHz. Through its reduced wavelength, it has 
been demonstrated that such high frequencies provide direct 
access to ultrasonic effects resulting from scattering from 
nanoscale acoustically-contrasting features. Following early 
results [4], an exploratory program based on US scanning of 
porcine tissue ex vivo with a typical frequency of 47 MHz is 
under way and has shown that the distinct layers within the GI 
tract can be imaged. The highly specialized single-element 
transducers for this work used 1-3 connectivity piezoceramic 
- polymer composite material made with micromoulding and 
casting processes. To avoid US artefacts whilst maintaining 
the sensitivity inherent in piezocomposites, these materials 
were designed with pseudo-random ceramic phase patterns 
[5]. These allow higher than usual frequencies to be achieved 
with viable ceramic dimensions. Additionally, successful in 
vivo testing has begun, with simpler piezopolymer 
transducers.  
To progress towards automated diagnosis, quantitative 
analysis of the scan data has been explored [6], focusing on 
measurement of acoustic impedance, attenuation and 
backscattering, with promising results presented in this paper. 
B. Fluorescence Marking and Imaging   
To explore the marking process [7], experiments were 
performed on ex vivo murine and porcine tissue using 
fluorescent CdSeS/ZnS quantum dots (QDs) (Sigma-Aldrich, 
USA). These were directed towards the focal zone of a 
miniature high intensity focused US (HIFU) transducer 
operating at 4 MHz. The results presented in this paper show 
preferential concentration where the US was applied.   
In the work outlined here, fluorescence imaging was based 
on the configuration of single-photon avalanche diode 
(SPAD) arrays with bespoke application-specific integrated 
circuits (ASICs) in miniaturized configurations for capsule 
deployment [8]. Successful demonstrations of both imaging 
and miniaturization are demonstrated.  
C. Therapeutic CE Device Feasibility  
To determine if the HIFU components for UmTDD can be 
incorporated in CE, and the extent of their capabilities, a 
prototype device was constructed. This included a confocal 
arrangement of: a HIFU source (Meggitt Sensing Systems, 
Kvistgaard, Denmark), diameter 4 mm, focal distance 6 mm, 
frequency 4 MHz; a miniature white light camera (Micro 
ScoutCam 1.2, Medigus, Omer, Israel), length 5 mm, diameter 
1.2 mm; and a delivery channel for agents mimicking drugs 
and drug-delivery vehicles [9].  
The prototype demonstrated that a stream of microbubbles 
could be directed towards a target based on US radiation force 
from the HIFU transducer, with an excitation level of 8 Vpp, 
compatible with the voltage amplitude that may be available 
in a CE device. Measuring transepithelial resistance in a 
model of the wall of the GI tract using Caco-2 cell monolayers 
showed that the same transducer with similar excitation levels 
could influence uptake in vitro [9].  
D. Ultrasound-mediated Targeted Drug Delivery  
A typical use for the clinical procedure outlined above is to 
deliver drugs to treat localized disease within the GI tract in a 
targeted manner. With UmTDD, this involves three 
mechanisms [10]: packaging of the drug to passivate it so that 
systemic effects will be reduced; physical direction of the 
packaged drug towards the treatment site; and reduction in the 
permeability of the target to enhance uptake. Additionally, it 
may be necessary to disrupt the drug - package complex so 
that the drug may be released and taken up by cells.  
An approach explored by the authors is to combine a drug 
with a nanoscale, chemically-engineered package. This is 
demonstrated through work on the creation of a chemical 
complex comprising the chemotherapeutic drug doxorubicin 
(Dox) and 5-cyclodextrin. With Dox on its own as a control, 
it is shown that the chemical complex has a reduced effect on 
cells in vitro whereas mildly hyperthermic and cavitational 
effects of US compatible with use in the GI tract enhanced the 
effect of the drug when applied as a nanoscale complex [11].   
IV. CONCLUSIONS  
A potential theranostic strategy for treatment of diseases 
of the GI tract based on the use of nanotechnology combined 
with CE has been outlined. This relies on US analysis of 
targets at the nanoscale, marking with nanoscale agents and 
delivery of nanoscale drug complexes for treatment. The 
clinical procedure involves multiple steps with development 
relying on multidisciplinary research. Progress in several 
directions is presented in this paper and further work is under 
way to demonstrate the viability of the procedure.  
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